Table 1.
Prognostic biomarkers in early-stage non-small cell lung cancer.
| Study | Biomarker (assay) | Study design (LOE) | Number of patients/ specimens | Stage of disease | Biomarker status | HR for overall survival (p value) |
|---|---|---|---|---|---|---|
| [Kamal et al. 2010] | MSH2 (IHC) | Retrospective analysis within IALT study (ΙΙ) | 1867/673 | I–III | High expression (H-score = 3) | 0.66 (0.01) |
| [Olaussen et al. 2006] | ERCC1 (IHC) | Retrospective analysis within IALT study (ΙΙ) | 1867/761 | I–III | Positive expression (H-score > median value) | 0.66 (0.009) |
| [Filipits et al. 2007a] | MRP2 (IHC) | Retrospective analysis within IALT study (ΙΙ) | 1867/782 | I–III | Positive expression (>0% positive tumor cells) | 1.37 (0.007) |
| [Tsao et al. 2007] | p53 (IHC) | Retrospective analysis within NCIC CTG-JBR.10 (ΙΙ) | 482/253 | IB–II | Positive expression (staining score≥ 15%) | 1.89 (0.03) |
| [Graziano et al. 2010] | p53 (IHC) | Retrospective analysis within CALBG 9633 (ΙΙ) | 344/250 | IB | Positive expression | 2.30 (0.0005) |
| [Seve et al. 2007] | βTUBIII (IHC) | Retrospective analysis within NCIC CTG-JBR.10 (ΙΙ) | 482/265 | IB–II | High expression (H-score > median value) | 1.72 (0.04) |
| [Graziano et al. 2010] | Mucin (IHC) | Retrospective analysis within CALBG-9633 (II) | 344/250 | IB | Positive expression | 2.03 (0.004) |
| [Cappuzzo et al. 2009] | MET (FISH) | Retrospective analysis of cohort data (ΙIΙ) | 447/435 | I–II | Negative (mean gene copy number <5 copies/cell) | 0.66 (0.04) |
| [Rosell et al. 2007] | BRCA1 (RT-qPCR) | Retrospective analysis of cohort data (ΙIΙ) | 126; 58 (validation cohort) | I–IIIA; IB–IIB | High expression (relative gene expression > median value) | 1.98 (0.02); 2.4 (0.04) |
BRCA1, breast cancer susceptibility gene 1; ßTUBIII, class III beta-tubulin; CALBG, Cancer and Leukemia Group B; ERCC1, endonuclease excision repair cross-complementing 1; FISH, fluorescent in situ hybidization; HR, hazard ratio; IALT, International Adjuvant Lung Cancer Trial; IHC, immunohistochemistry; LOE, level of evidence for grading clinical utility of tumor markers [Hayes et al. 1996]; MET, hepatocyte growth factor receptor; MRP2, multidrug resistance protein 2 MSH2; MutS homolog 2; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; p53, tumor protein 53; RT-qPCR, real-time quantitative polymerase-chain reaction.